Last updated: July 31, 2026
Theophylline-SR is a mature sustained-release oral formulation of theophylline used primarily in asthma and chronic obstructive pulmonary disease. Its clinical-development profile is limited: no major modern pivotal program is driving the product, and current guideline use is restricted by narrow therapeutic margins, drug interactions, and safer inhaled alternatives. The commercial market is generic, fragmented, and declining in strategic importance.
A defensible global revenue figure for Theophylline-SR alone is not publicly available because manufacturers report the product within broader respiratory or generic portfolios. The most supportable projection is a low-value, declining market with continued demand in selected low-cost and resource-constrained settings.
What is Theophylline-SR and how does it work?
Theophylline-SR is an extended-release oral formulation of theophylline, a methylxanthine bronchodilator. Sustained-release delivery reduces dosing frequency and produces more stable plasma concentrations than immediate-release tablets.
The drug has several pharmacologic effects:
- Bronchodilation through phosphodiesterase inhibition and adenosine-receptor antagonism.
- Modest improvement in diaphragmatic contractility.
- Possible anti-inflammatory effects at low concentrations.
- Narrow separation between therapeutic and toxic concentrations.
Theophylline is metabolized mainly through CYP1A2, with contributions from CYP3A4 and CYP2E1. Clearance changes with age, smoking, fever, liver disease, heart failure, and interacting medicines. Cigarette smoking can increase clearance, while smoking cessation can raise theophylline exposure. Macrolide antibiotics, fluoroquinolones, cimetidine, and other medicines can also alter concentrations.[1]
Extended-release products are not uniformly interchangeable. Release characteristics, bioavailability, tablet strength, and dosing intervals can differ between manufacturers. Product substitution should follow applicable regulatory requirements and prescribing information.
What is the current FDA regulatory status of Theophylline-SR?
Theophylline extended-release products are approved prescription medicines in the United States. They are marketed through multiple abbreviated new drug applications and legacy branded or authorized-generic products.
The principal regulatory characteristics are:
| Regulatory issue |
Current assessment |
| Active ingredient |
Theophylline |
| Dosage form |
Extended-release oral tablet or capsule, depending on product |
| FDA pathway |
Legacy NDA products and ANDA generic products |
| Therapeutic category |
Bronchodilator |
| Primary indications |
Asthma and reversible airflow obstruction; some products include COPD-related indications |
| Controlled substance status |
Not a controlled substance |
| Pediatric status |
Product-specific; dosing requires age and weight adjustment |
| Generic availability |
Broad |
| New-drug exclusivity |
Expired for legacy products |
| Regulatory differentiation |
Primarily formulation, strength, manufacturing, and labeling differences |
The FDA-approved labeling emphasizes serum-concentration monitoring, gradual dose adjustment, and attention to interactions. Toxicity may produce nausea, vomiting, tremor, insomnia, tachycardia, arrhythmia, seizures, and, at severe concentrations, death.[1]
Current asthma guidance generally places oral theophylline below inhaled corticosteroids, inhaled bronchodilators, leukotriene receptor antagonists, and biologic therapies because efficacy is less favorable and adverse-event risk is higher.[2] The GOLD strategy for COPD also limits the role of theophylline because of modest efficacy and clinically important toxicity.[3]
Are there active clinical trials for Theophylline-SR?
No contemporary late-stage development program appears to be supporting Theophylline-SR as a new product. The clinical evidence base is predominantly historical, postmarketing, or focused on theophylline as an active ingredient rather than on a proprietary sustained-release product.
Clinical-trial activity falls into four categories:
| Trial category |
Development relevance |
| Historical asthma and COPD efficacy studies |
Established bronchodilator activity but predate current inhaled-treatment standards |
| Pharmacokinetic and bioequivalence studies |
Relevant to generic approval and product substitution |
| Low-dose anti-inflammatory studies |
Investigational and not sufficient to establish a new commercial indication |
| Combination or comparative studies |
Limited strategic value because inhaled therapies dominate treatment algorithms |
ClinicalTrials.gov is the main U.S. registry for identifying ongoing studies, but registered studies may involve theophylline as a comparator, background medicine, or mechanistic research agent rather than as an active development program.[4]
The commercial implication is clear: Theophylline-SR is a maintenance generic product, not a pipeline asset. Its value depends on supply continuity, manufacturing economics, regional demand, and regulatory compliance rather than on new clinical differentiation.
What clinical evidence supports extended-release theophylline?
Theophylline can improve airflow and symptoms in asthma and COPD, but its therapeutic benefit is generally smaller and less predictable than that of inhaled therapies.
Historical studies established that sustained-release theophylline can:
- Improve forced expiratory volume in one second.
- Reduce nocturnal symptoms in some patients.
- Provide modest bronchodilation over a dosing interval.
- Reduce the need for short-acting bronchodilator use in selected patients.
The principal limitations are pharmacokinetic variability and dose-related toxicity. The product has a relatively narrow therapeutic window, and the relationship between blood concentration, benefit, and toxicity varies among patients.
The drug is most likely to retain a clinical role where:
- Inhaled medicines are unavailable or unaffordable.
- Patients cannot use inhaler devices effectively.
- Clinicians require an inexpensive oral bronchodilator.
- Existing patients are stable on treatment and monitoring is available.
It is less competitive where inhaled corticosteroids, long-acting bronchodilators, combination inhalers, and biologics are accessible.
When does Theophylline-SR lose exclusivity?
Theophylline-SR has no meaningful remaining brand exclusivity in the United States. The active ingredient and the underlying sustained-release concept have been commercially available for decades, and generic products are established.
Patent and Orange Book position
The Orange Book can list patents for approved drug products, but the key commercial question for Theophylline-SR is not whether any historical formulation patent existed. It is whether an unexpired, enforceable patent or regulatory exclusivity currently blocks generic substitution or launch.
For the mature theophylline extended-release market:
- Core composition-of-matter protection has expired.
- Legacy formulation patents are generally expired.
- New-drug exclusivity has expired.
- Generic competition is established.
- Any remaining patent issue would be product-specific rather than a market-wide barrier.
No patent estate comparable to a modern inhaled combination product protects the broad Theophylline-SR market. Patent diligence should focus on the specific manufacturer, strength, release profile, capsule or tablet technology, and applicable national register.
What formulation patents protect Theophylline-SR products?
Potentially relevant intellectual-property categories include:
- Extended-release matrix systems.
- Coated granules or multiparticulate capsules.
- Controlled-dissolution polymers.
- Tablet compression and coating processes.
- Stability and packaging systems.
- Specific dose strengths or dosing schedules.
- Manufacturing methods that control dissolution profiles.
These categories may have supported historical products, but they do not create broad current exclusivity for theophylline extended-release products. A generic applicant would generally address formulation protection through an ANDA strategy, design-around, patent certification, or litigation analysis specific to the reference product.
The most important technical barrier is often regulatory bioequivalence rather than patent protection. Extended-release products must demonstrate acceptable pharmacokinetic performance and, where required, dissolution similarity. Failure to match release behavior can cause clinically meaningful exposure differences.
Are there Paragraph IV challenges involving Theophylline-SR?
Theophylline-SR is not a current high-value Paragraph IV market. Generic entry occurred long ago, and the major branded products no longer have the commercial profile that typically generates extensive modern ANDA litigation.
A Paragraph IV certification may still arise for a specific product if a manufacturer lists an unexpired patent in the Orange Book. Such a certification would not necessarily affect the broader theophylline market because multiple generic and legacy products are available.
The litigation risk is therefore product-specific:
| Risk category |
Assessment |
| Broad market blockade |
Low |
| Core active-ingredient patent risk |
Negligible |
| Historical formulation patent risk |
Generally expired |
| Product-specific release technology |
Possible, depending on listing |
| ANDA litigation value |
Low relative to branded inhaled respiratory products |
| Launch-at-risk economics |
Usually limited by low market value |
Which companies manufacture or market Theophylline-SR?
The market has included branded, authorized-generic, and unbranded generic suppliers. Historical U.S. brands include Theo-24, Uniphyl, and Slo-Bid, although availability varies by time, product strength, and distributor.
The commercial supply base can include:
- U.S. generic prescription manufacturers.
- Contract manufacturing organizations.
- Regional pharmaceutical companies.
- Importers and distributors.
- Manufacturers serving hospital and public-sector tenders.
Supplier concentration can change because the product is inexpensive and manufacturing margins are limited. A manufacturer may discontinue a strength without abandoning the active ingredient. This creates periodic shortage or allocation risk even when patent barriers are absent.
The most important competitive variables are price, dependable supply, tablet or capsule strengths, dissolution performance, regulatory compliance, and distribution reach.
What is the market outlook for Theophylline-SR?
The global Theophylline-SR market should be analyzed as a mature generic niche rather than a growth pharmaceutical market.
2024-2029 indexed projection
Because manufacturers do not separately disclose Theophylline-SR sales, the following projection uses 2024 market value as an index of 100 rather than presenting an unsupported dollar estimate.
| Scenario |
2025 |
2026 |
2027 |
2028 |
2029 |
Strategic interpretation |
| Base case |
96 |
92 |
88 |
84 |
80 |
Gradual volume decline and price erosion |
| Downside |
92 |
84 |
77 |
70 |
64 |
Faster conversion to inhaled therapies and supplier exits |
| Resilient-access case |
99 |
98 |
97 |
96 |
95 |
Stable demand in low-cost and limited-access markets |
The base case implies a compound annual decline of approximately 4.3% from 2024 through 2029. The resilient-access scenario assumes continuing use where oral therapy is less expensive or inhaler access is limited.
Revenue exposure
Revenue exposure is concentrated in:
- High-volume, low-margin generic prescriptions.
- Government and institutional procurement.
- Markets with limited access to inhaled maintenance products.
- Existing patients who remain clinically stable on oral therapy.
- Suppliers with low-cost manufacturing and established distribution.
The product has little exposure to premium pricing, specialty pharmacy, biologic competition, or indication expansion.
How does Theophylline-SR compare with competing respiratory drugs?
| Product class |
Clinical position |
Commercial position |
Competitive effect on Theophylline-SR |
| Inhaled corticosteroids |
Core anti-inflammatory asthma therapy |
Established branded and generic markets |
Strong substitution pressure |
| Long-acting beta agonists |
Maintenance bronchodilation |
Strong combination-product economics |
Strong substitution pressure |
| LAMA therapies |
Important COPD maintenance option |
Generic and branded competition |
Strong substitution pressure |
| Leukotriene receptor antagonists |
Oral alternative in selected asthma patients |
Generic, convenient dosing |
Moderate substitution pressure |
| Biologic therapies |
Severe eosinophilic or allergic asthma |
High-value specialty market |
Limited direct overlap, but removes severe patients |
| Oral theophylline |
Low-cost, narrow therapeutic window |
Mature generic niche |
Residual-access role |
Theophylline-SR may retain an adherence advantage for patients who prefer oral dosing, but inhaler technique and adherence problems are usually addressed through device selection, education, or combination inhalers rather than by returning to theophylline.
What generic launch risks exist for Theophylline-SR?
Generic launch risk is low from an intellectual-property perspective and moderate from an operational perspective.
Intellectual-property risk
The principal risks are:
- A product-specific unexpired formulation patent.
- A dissolution or release profile that is difficult to replicate.
- Orange Book listing differences between reference products.
- State or national substitution rules.
- Litigation involving a particular NDA holder.
Regulatory and manufacturing risk
More material risks include:
- Failure to demonstrate bioequivalence.
- Batch-to-batch dissolution variability.
- Dose dumping under altered gastrointestinal conditions.
- Stability problems.
- Manufacturing-site inspection findings.
- API supply interruptions.
- Low market prices that discourage multiple suppliers.
The small market may reduce the economic incentive for new entrants even where legal barriers are absent. A successful entrant would need reliable API sourcing, efficient production, competitive pricing, and sufficient volume to justify regulatory maintenance.
What is the geographic outlook for Theophylline-SR?
Demand is likely to remain strongest in countries where inhaled medicines are less accessible or where oral generics are favored by procurement systems.
Higher-retention markets
- South Asia.
- Parts of Southeast Asia.
- Selected Latin American markets.
- Lower-income public-health systems.
- Regions with limited respiratory-device access.
Lower-retention markets
- United States.
- Western Europe.
- Japan.
- Other markets with broad access to inhaled corticosteroid and long-acting bronchodilator therapy.
Regulatory status varies by jurisdiction. Some countries retain theophylline on essential-medicine or national formulary lists, while others restrict routine use because of toxicity and monitoring requirements.
What is the litigation and settlement outlook?
Theophylline-SR has a low probability of material new patent litigation. The market lacks the combination of high sales, dense recent patents, and exclusivity value that commonly produces Paragraph IV settlements.
If litigation arises, likely issues include:
- Whether a release-control patent is enforceable.
- Whether a generic product infringes a specific dissolution or formulation claim.
- Whether a listed patent is properly tied to the approved product.
- Whether the reference product and proposed generic are therapeutically substitutable.
- Whether a supplier can launch after resolving regulatory deficiencies.
Settlement economics are likely to be modest compared with respiratory products such as inhaled corticosteroid/LABA combinations, LAMA/LABA products, or biologics.
Key Takeaways
- Theophylline-SR is a mature extended-release generic, not an active late-stage development asset.
- Modern clinical use is limited by toxicity, interactions, pharmacokinetic variability, and stronger inhaled alternatives.
- No broad remaining patent or exclusivity barrier is expected to protect the market.
- Paragraph IV and settlement risk is low at the market level, although product-specific patents require separate review.
- The market is likely to decline gradually through 2029, with residual demand in cost-sensitive and access-constrained regions.
- Manufacturing reliability, bioequivalence, dissolution control, and API supply are more important than patent exclusivity.
- A base-case indexed projection declines from 100 in 2024 to approximately 80 in 2029.
FAQs
Is Theophylline-SR still prescribed for asthma?
Yes. It remains available and is prescribed selectively, mainly when inhaled therapies are unsuitable, unavailable, or unaffordable. It is not a preferred routine controller in contemporary asthma treatment guidance.[2]
Can Theophylline-SR be substituted between manufacturers?
Substitution depends on the applicable regulatory and pharmacy rules. Extended-release products should not be assumed to have identical release characteristics solely because they contain the same dose of theophylline.
Does Theophylline-SR have biosimilar competition?
No. Theophylline is a small-molecule drug. Competition occurs through generic drug pathways, not biosimilar pathways.
Is Theophylline-SR a candidate for reformulation?
Possible reformulation opportunities include improved release control, reduced interaction risk, simplified monitoring, and combination therapy. Commercial prospects are limited by the low price of generic theophylline and the clinical preference for inhaled products.
Does smoking affect Theophylline-SR dosing?
Yes. Smoking can increase theophylline clearance, while smoking cessation can increase exposure. Dose changes and serum-concentration monitoring may be required when smoking status changes.[1]
References
-
U.S. Food and Drug Administration. (n.d.). Theophylline extended-release tablets and capsules: Prescribing information. FDA labeling database.
-
Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. Global Initiative for Asthma.
-
Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the prevention, diagnosis and management of chronic obstructive pulmonary disease. GOLD.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/
